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Myelodysplastic syndromes (MDS) are a group of hematological disorders characterized by progressive cytopenia and increased tendency of acute myeloid leukemia (AML) transformation.
1
While the majority of patients are diagnosed with low-grade disease, approximately two-thirds will succumb to complications of peripheral blood cytopenia or progression into AML. That is why the phenotype of high risk MDS has often been associated with some AML features. However, a unique aspect of MDS is the notion that both bone marrow failure and the propensity towards development of AML coexist. As both properties contribute to peripheral blood cytopenia and the natural history of the disease, it is thought that proliferative advantages lend themselves more to leukemic transformation, while initially accelerated apoptosis is responsible for the cytopenia. 1 It is likely that aberrant regulation of intracellular signaling pathways is involved in the pathogenesis of MDS.
The phosphatidylinositol-3 kinase (PI3K)/Akt network plays a fundamental role in antiapoptotic signaling. In fact, the serine/ threonine kinase Akt, a downstream effector of PI3K, is the best characterized mammalian antiapoptotic kinase and has been implicated in the aggressiveness of a number of different human cancers, including hematological malignancies.
2 Accordingly, it has been recently demonstrated that activation of the PI3K/Akt axis is critical for both cell survival and proliferation not only in AML, 3 but also in high-risk MDS cases. Indeed, patients affected by high-risk MDS frequently demonstrated an activation of Akt, 4 as well as of mammalian target of Rapamycin (mTOR) and its downstream targets, that is, 4E-binding protein 1 and p70 ribosomal S6 kinase, when compared with low-risk MDS patients and healthy donors. 5 In particular, the mTOR pathway was specifically upregulated in the hematopoietic myeloid progenitors of high-risk MDS patients, since rapamycin (an mTOR inhbitor) increased the percentage of apoptotic CD33 þ cells as well as negatively affected the clonogenic activity of CD34 þ MDS cells by reducing the size and number of the colonies. These results indicated that in high-risk MDS patients the Akt/mTOR pathway is overactivated, thus leading to an imbalance in the apoptotic process. Therefore, this survival network is likely to play an important role in the MDS pathogenesis and contribute to the malignant growth of MDS cells, even though it is unlikely to be the only one pathway involved in MDS progression. In fact, our recent findings have highlighted that in high risk MDS patients there also is an inverse correlation between the amount of phosphoinositide-specific phospholipase C b1 and Akt. 6 Scarce attention has been so far paid to the possible activation of pro-apoptotic kinases in MDS patients. Phosphorylation of eukaryotic translation initiation factor (eIF2)a by members of the eIF2a kinase family results in inhibition of translation initiation by reducing the levels of functional eIF2, thus contributing to apoptosis. There are four kinases which can phosphorylate eIF2a in response to stress signals: the heme-regulated inhibitor (HRI), the general control nonderepressible-2, the PKR-like endoplasmic reticulum resident kinase, and the protein kinase activated by double-stranded RNA (PKR). As for this latter, in addition to its translational regulatory function, PKR is known to play a role in signal transduction and transcriptional control, mainly through the NF-kB or ERK pathways. 7 PKR is mainly localized in the cytoplasm, but about 20% is nuclear. The functional role of nuclear PKR is still unknown, even though the presence of both nuclear localization and export signals suggest that the regulation of nuclear PKR might have important physiological roles. 7 Other studies have reported increased PKR expression and activity levels in colon and breast cancer, as well as in melanoma and hepatocellular carcinoma. 7 PKR activity depends on autophosphorylation of Thr 446/451 residues. Because of the very limited number of MDS bone marrow mononuclear cells (BMMC) available for each patient, we analyzed the levels of both total PKR and phosphorylated PKR (p-PKR) by means of fluorescence immunocytochemistry, 4 using healthy donors as controls for comparison of staining intensity. The specificity of the antibodies, and in particular of the phospho-specific antibody, was tested first on CEM and HL60 cells, by means of both western blot and immunocytochemistry analyses (Supplementary Figure 1) . We analyzed a total of 22 patients, affected by either low-risk MDS (n ¼ 10) or high-risk MDS (n ¼ 12), diagnosed according to the International Prognostic Scoring System 1 and the French-American-British classification. Their median age was 71.8 (range, 48-90) and the male/female ratio was 17/5. In all, 12 of them had a normal karyotype, while the others had some karyotype alterations: trisomy 8 (n ¼ 2), À5q (n ¼ 1), trisomy 21 (n ¼ 1), and six of them had more than three chromosomal alterations (n ¼ 6, named as complex) Immunostaining with Thr451 p-PKR antibody. The levels of total PKR were similar to those observed in healthy donors and low-risk MDS. As for p-PKR, MDS cells demonstrated both cytoplasmic and nuclear localization: some cells displayed a nuclear staining (arrowhead), whereas others showed a predominant cytoplasmic localization (arrow).
( Table 1 ). The levels of total PKR were similar in all of the MDS samples analyzed when compared with BMMC from healthy donors (Figures 1a and 2a) . In contrast, while BMMC from healthy donors contained very low levels of p-PKR, an increase in the amount of p-PKR was detected in low-risk MDS patients ( Figure 1b and Table 1 ). Interestingly, high-risk MDS cells showed not only an increased amount, but also a different subcellular localization, of p-PKR (Figure 2b and Table 1 ). In fact, in these patients, about 50% of BMMC displayed a nuclear localization of p-PKR, whereas in low risk MDS patients and in healthy donors the staining was exclusively detected in the cytoplasm ( Figure 1 and Table 1 ). Our findings suggest that PKR could be somehow involved in the increased apoptosis seen in low risk MDS patients. Indeed, BMMC from low-risk MDS patients show increased levels of p-eIF2a when compared with healthy donors (data not shown). As to nuclear localization of p-PKR in BMMC from high-risk MDS patients, who are characterized by a lower apoptotic rate, it has been hypothesized that the nuclear translocation may be a mechanism to sequester active kinases, thus preventing upregulation of cytosolic signaling pathways. This is the case for phosphoinositide-dependent protein kinase-1, whose nuclear localization has been suggested to inhibit Akt-mediating signalling. 8 Therefore, it might be that active (phosphorylated) PKR is sequestered in the nucleus of BMMC from high risk MDS patients, who are characterized by a lower apoptotic rate. However, we could not rule out that nuclear localization of p-PKR in high-risk MDS patients is somehow linked to disease progression to AML. Further investigations are therefore needed to fully understand the functional role of PKR in both low-risk and high-risk MDS patients, nevertheless our findings suggest that also this protein kinase could be involved in the pathogenesis of MDS.
